Despite encouraging clinical results, copyright's Vyndamax, a medication for hereditary transthyretin-mediated amyloidosis (hATTR), is encountering significant opposition from PBMs. The organizations are frequently building obstacles to reimbursement, such as steep cost restrictions and PA that restrict consumer availability. Industry indicate t… Read More